ArticleJournal of medical cases2021
Hypercoagulopathy in COVID-19, Deep Venous Thrombosis After Extra-Corporeal Membrane Oxygenation Therapy: A Case Report.
Article in Journal of medical cases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus that has caused a pandemic across the world in the years 2019 - 2020 with over 100 countries reporting high infection rates. The virus is unique in the wide spectrum of disease manifestations it can cause; one of the worst of which is the hypercoagulable state induced by severe infection. This case report focuses on a 33-year-old Hispanic male who developed severe acute respiratory syndrome requiring management with extracorporeal membrane oxygenation (ECMO) and developed deep venous thromboses during severe coronavirus disease 2019 (COVID-19) pneumonia. Since there are no current guideline(s) for routine screening for venous thromboembolism (VTE) in ECMO patients, we aim to highlight a proposed benefit of routine screening for VTE in patients with severe COVID-19 treated with ECMO pre-cannulation and post-decannulation, which minimizes the risk of cannulation-associated complications, as well as the risk of post-decannulation VTE respectively. While VTE is a known complication of ECMO therapy, the rates of increased incidence of VTE in patients with severe COVID-19 make the detection of such complications even more important to reduce overall morbidity and mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.